# A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

> **NCT02025192** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 60 (actual)

## Conditions studied

- HER2 Positive Metastatic Breast Cancers

## Interventions

- **DRUG:** Tucatinib
- **DRUG:** Capecitabine
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02025192
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-31
- **Primary completion:** 2017-10-03
- **Final completion:** 2020-03-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025192, "A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02025192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*